GSK and Flagship Join Forces to Innovate Future Drugs and Vaccines

GSK and Flagship Pioneering, a bioplatform innovation business, today announced that they have partnered to find and create a portfolio of transformative future drugs and vaccines, beginning with immunology and respiratory treatments.Through this partnership, significant advancements in healthcare will be made by combining GSK's disease area knowledge and development competence with Flagship's network of bioplatform firms, including its cutting-edge modalities and technologies.

To support an exploratory phase aimed at identifying the most promising concepts for additional research and development with Flagship's bioplatform firms, GSK and Flagship have agreed to provide up to $150 million in upfront funding.Through these investigations, the partnership hopes to find a portfolio of up to ten innovative drugs and vaccines, each of which will have an exclusive option granted by GSK for additional clinical development. In accordance with the terms of the agreement, GSK will pay Flagship and its bioplatform firms up to $720 million in upfront development and commercial milestones, preclinical financing, and tiered royalties for each initiative that is purchased.

"Together with Flagship, we will use science and technology to deliver best-in-class innovation at pace," stated Tony Wood, Chief Scientific Officer of GSK. We are eager to collaborate with Flagship's brilliant staff and network of bioplatform businesses in order to quicken our pipeline and find treatments and vaccines that will revolutionise patient care.

Flagship and GSK have a same goal of providing patients with innovative medicines, according to Paul Biondi, President of Pioneering Medicines and General Partner at Flagship Pioneering. This partnership is the most recent implementation of Flagship's Innovation Supply Chain Partnership model, which is intended to produce transformative drugs in conjunction with our pharmaceutical partners by utilising our network of leading bioplatforms to establish a long-term supply of therapies for patients with the greatest unmet needs.